EUVIMEDEUVIMED entdecken
Open Access

Advanced Glycation End‐Product Carboxymethyl‐Lysine and Incident Heart Failure and Atrial Fibrillation in Older Adults

Yakubu Bene-Alhasan iD, Traci M Bartz iD, Luc Djoussé iD, Joachim Ix iD, David Siscovick iD, John S Gottdiener, Russell P Tracy iD, Calvin H Hirsch iD, Anne B Newman iD, Sanjiv J Shah iD, Susan R Heckbert iD, Kenneth J Mukamal iD und 1 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.040640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Yakubu Bene-Alhasan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Research, Department of Medicine Baylor College of Medicine Houston TX USA. Hauptthemen laut MEDLINE: Glycation End Products, Advanced, Lysine, Heart Failure, Atrial Fibrillation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advanced glycation end‐products result from chemical modification of proteins under conditions of hyperglycemia or oxidative stress common with advancing age. Advanced glycation end‐product (AGE) formation alters vascular and cardiac structure and function, yet the prospective associations of circulating AGEs with heart failure (HF) and atrial fibrillation (AF) have not been studied.

Methods

We evaluated the associations of serum N ε ‐carboxymethyl‐lysine (CML), a major AGE in tissue proteins, and incident HF and AF in the CHS (Cardiovascular Health Study), a population‐based cohort of older adults. HF subtypes were examined secondarily, as were prevalent echocardiographic phenotypes. CML was measured by immunoassay.

Results

Among 2685 eligible participants (age 77±5; 63% women; 17% with diabetes), 832 HF and 1016 AF events occurred over a median follow‐up of 9 years. After adjustment for potential confounders, serum CML was associated with a higher risk of incident HF and AF (hazard ratio per SD, 1.10 and 1.09 [95% CI, 1.02–1.17 and 1.02–1.16], respectively). The association with AF was attenuated and nonsignificant after adjusting for estimated glomerular filtration rate and urine albumin–creatinine ratio. The CML–HF relation was similarly attenuated after adjusting for time‐updated myocardial infarction. Both associations were nonsignificant after adjusting for natriuretic peptides or excluding those with elevated levels at baseline. Secondary analyses of incident HF subtypes or baseline cardiac mechanics showed no significant associations.

Conclusions

In older adults, serum CML was prospectively associated with higher risk of HF and AF independent of potential confounders, with evidence of attenuation by certain putative mediators. AGEs and AGE‐countering therapies merit additional evaluation in this high‐risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycation End Products, AdvancedLysineHeart FailureAtrial FibrillationIncidenceBiomarkersFollow-Up StudiesHumansMaleFemaleAgedAged, 80 and overConfounding Factors, EpidemiologicGlomerular Filtration RateAlbuminuriaCreatinineNatriuretic PeptidesRisk AssessmentUnited States

Stichwörter der Autor:innen

atrial fibrillationcardiac mechanicscardiovascular diseasecardiovascular health studygeriatric cardiologyheart failurepreventive cardiology

Substanzen

Glycation End Products, AdvancedN(6)-carboxymethyllysineLysineBiomarkersCreatinineNatriuretic Peptides

Autor:innen und Institutionen

  • Section of Cardiovascular Research, Department of Medicine Baylor College of Medicine Houston TX USA.
  • Department of Medicine, Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA.
  • Department of Biostatistics University of Washington Seattle WA USA.
  • Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
  • Department of Medicine University of California San Diego and Veterans Affairs San Diego Healthcare System San Diego CA USA.
  • The New York Academy of Medicine New York NY USA.

ORCID-Profile: Yakubu Bene-Alhasan, Traci M Bartz, Luc Djoussé, Joachim Ix, David Siscovick, Russell P Tracy, Calvin H Hirsch, Anne B Newman, Sanjiv J Shah, Susan R Heckbert, Kenneth J Mukamal, Jorge R Kizer

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS

Zitieren

APA

Bene-Alhasan, Y., Bartz, T. M., Djoussé, L., Ix, J., Siscovick, D., Gottdiener, J. S., Tracy, R. P., Hirsch, C. H., Newman, A. B., Shah, S. J., Heckbert, S. R., Mukamal, K. J., & Kizer, J. R. (2025). Advanced Glycation End‐Product Carboxymethyl‐Lysine and Incident Heart Failure and Atrial Fibrillation in Older Adults. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040640

Vancouver

Bene-Alhasan Y, Bartz TM, Djoussé L, Ix J, Siscovick D, Gottdiener JS, et al. Advanced Glycation End‐Product Carboxymethyl‐Lysine and Incident Heart Failure and Atrial Fibrillation in Older Adults. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040640

BibTeX
@article{BeneAlhasan2025,
  author = {Bene-Alhasan, Yakubu and Bartz, Traci M and Djoussé, Luc and Ix, Joachim and Siscovick, David and Gottdiener, John S and Tracy, Russell P and Hirsch, Calvin H and Newman, Anne B and Shah, Sanjiv J and Heckbert, Susan R and Mukamal, Kenneth J and Kizer, Jorge R},
  title = {Advanced Glycation End‐Product Carboxymethyl‐Lysine and Incident Heart Failure and Atrial Fibrillation in Older Adults},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.040640}
}
Kostenlos starten →